Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Public ClinicalTrials.gov record NCT02272790. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicentre Phase II Study of Adavosertib Plus Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Adavosertib in combination with carboplatin, paclitaxel, gemcitabine, or PLD.
Study identification
- NCT ID
- NCT02272790
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 95 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 130 Years
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 30, 2015 (Actual)
- Primary completion
- Dec 13, 2018 (Actual)
- Completion
- Mar 8, 2023 (Actual)
- Last update posted
- Oct 3, 2023
2015 – 2023
United States locations
- U.S. sites
- 18
- U.S. states
- 13
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Gilbert | Arizona | 85234 | — |
| Research Site | Tucson | Arizona | 85724 | — |
| Research Site | La Jolla | California | 92093 | — |
| Research Site | Los Angeles | California | 90024 | — |
| Research Site | San Francisco | California | 94158 | — |
| Research Site | Tampa | Florida | 33612 | — |
| Research Site | West Palm Beach | Florida | 33401 | — |
| Research Site | Augusta | Georgia | 30912 | — |
| Research Site | Boston | Massachusetts | 02215 | — |
| Research Site | Detroit | Michigan | 48201 | — |
| Research Site | New York | New York | 10019 | — |
| Research Site | New York | New York | 10065 | — |
| Research Site | Cleveland | Ohio | 44195 | — |
| Research Site | Oklahoma City | Oklahoma | 73104 | — |
| Research Site | Abington | Pennsylvania | 19001 | — |
| Research Site | Nashville | Tennessee | 37203 | — |
| Research Site | Dallas | Texas | 75390 | — |
| Research Site | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02272790, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 3, 2023 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02272790 live on ClinicalTrials.gov.